Switch to Health Care Professionals
Email Page
Print PageRituxan Access Solutions—Committed to Helping You Access Rituxan (rituximab)
- Useful Links
- Forms and Documents
- What's New?
- Medicare Appointment of Representative (AOR)
- Find out more about Rituxan Access Solutions
- Learn about co-pay assistance
- FDA approves use of Rituxan for first line treatment of follicular, CD20-positive, B-cell non-Hodgkin's lymphoma in combination with CVP chemotherapy
- FDA approves use of Rituxan for treatment of low-grade, CD20-positive, B-cell non-Hodgkin's lymphoma in patients with stable disease or who achieve a partial or complete response following first line treatment with CVP chemotherapy.
Understanding how to access and pay for your medication can be challenging. Rituxan Access Solutions is here to help you understand your options and the process.
Coverage and Reimbursement
Rituxan Access Solutions helps resolve specific access and reimbursement issues for individual patients every day. Our specialists are passionate about helping you access Rituxan and exploring every appropriate solution to coverage or reimbursement issues.
Patient Assistance
To learn more about our patient assistance programs, please click on the button that applies to you.
- I’m uninsured or my health insurance denied my coverage
- I have health insurance and need help with my co-pay*
If you have questions about your disease and your Rituxan treatment, the CancerCare Program can offer counseling, education and practical help free of charge. For more information, click here.
Informational Resources
We all know it’s important to have the right information at your fingertips. With this in mind, we’ve compiled a list of informational resources you may find useful.
Rituxan (Rituximab) INDICATIONS AND USAGE
Non-Hodgkin's Lymphoma (NHL)
Rituxan® is indicated for the treatment of patients with:
- Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent
- Previously untreated follicular, CD20-positive, B-cell NHL in combination with CVP chemotherapy
- Non-progressing (including stable disease), low-grade, CD20-positive B-cell NHL, as a single agent, after first-line CVP chemotherapy
- Previously untreated diffuse large B-cell, CD20-positive NHL in combination with CHOP or other anthracycline-based chemotherapy regimens
Rituxan Boxed WARNINGS and Additional Important Safety Information
The most important serious adverse reactions of Rituxan are fatal infusion reactions, tumor lysis syndrome (TLS), severe mucocutaneous reactions, progressive multifocal leukoencephalopathy (PML), hepatitis B reactivation with fulminant hepatitis, other viral infections, cardiovascular events, renal toxicity, and bowel obstruction and perforation. The most common adverse reactions of Rituxan (incidence ≥25%) observed in patients with NHL are infusion reactions, fever, chills, infection, asthenia, and lymphopenia. The most common adverse reactions of Rituxan observed in patients with RA are hypertension, nausea, upper respiratory tract infection, arthralgia, pruritus, and pyrexia.
Attention healthcare provider: Provide Medication Guide to patient prior to Rituxan infusion.
For additional safety information, please see the full prescribing information, including Boxed WARNINGS and Medication Guide.
*Co-pay refers to a cost-sharing arrangement in which members of health insurance plans pay a specified charge for a product or service, such as a prescription or an office visit. Members are typically responsible for this payment at the time of service.
Privacy information: Any information submitted to Rituxan Access Solutions will remain confidential and will not be used for promotional purposes.
If you would like to learn more about protecting the privacy of personal health information, please go to the U.S. Department of Health & Human Services website at www.hhs.gov/ocr/hipaa/
